GSK's RSV Vaccine Arexvy Approved in Japan for Adults Aged 60 and Older

GSK announced on September 25 that Japan's Ministry of Health, Labour and Welfare has approved the Arexvy vaccine for the prevention of RSV (respiratory syncytial virus) disease in adults aged 60 and above. This is the first approval of an RSV vaccine for the elderly in Japan.